Olema Pharmaceuticals, Inc. SEC Filings

Olema Pharmaceuticals (OLMA) furnished an update on its business by reporting financial results for the quarter ended September 30, 2025. The company submitted a Current Report on Form 8-K under Item 2.02 and included a press release as Exhibit 99.1. The disclosure is designated as furnished, not filed, under the Exchange Act, meaning it is not subject to Section 18 liabilities and is incorporated by reference only if specifically stated.

Olema Pharmaceuticals (OLMA) reported updated Phase 1b/2 results for palazestrant combined with ribociclib in ER+/HER2- advanced or metastatic breast cancer. As of July 8, 2025, 72 patients were enrolled across 90 mg and 120 mg palazestrant dose cohorts alongside ribociclib 600 mg daily.

Efficacy in the 120 mg cohort (median follow-up >19 months) showed mature results with median progression-free survival (mPFS) of 15.5 months for all patients. Among those previously treated with CDK4/6 inhibitors, mPFS was 12.2 months, including 9.2 months for ESR1 wild-type tumors and 13.8 months for ESR1-mutant tumors. In the 90 mg cohort (median follow-up 10.8 months), mPFS was not reached.

The combination was well tolerated with no new safety signals, no observed drug–drug interactions, and mostly grade 1–2 adverse events, consistent with known profiles. These findings support the ongoing pivotal Phase 3 OPERA-02 trial of palazestrant plus ribociclib in frontline ER+/HER2- metastatic breast cancer.

Olema Pharmaceuticals director Cyrus Harmon reported open-market sales totaling 25,000 common shares across two trading dates in September 2025, reducing his direct holdings from 754,140 to 744,140 shares and his indirect holdings (via Harmon Family Investors LLC, which he manages) from 120,114 to 117,028 shares. The reported weighted-average sale prices ranged from about $8.02 to $8.37, with specific weighted averages of $8.04 and $8.33 for direct sales and $8.08 and $8.32 for indirect sales. The Form 4 discloses the manager relationship for the indirect holdings and provides ranges and weighted averages for the trades.

Olema Pharmaceuticals (OLMA) filed a Form 144 proposing the sale of 13,086 common shares. The sale is to be executed through Fidelity Brokerage Services with an approximate aggregate market value of $108,977.56 and an intended sale date of 09/18/2025. The company reports 68,634,329 shares outstanding, making the proposed sale a small portion of outstanding stock. The filer acquired 10,000 shares as founders shares on 03/20/2007 (compensation) and 3,086 shares in an open-market purchase on 06/30/2014 (cash). The filing also discloses recent sales on 09/16/2025: 10,000 shares by Cyrus L. Harmon for $80,362.60 and 1,914 shares by Harmon Family Investors LLC for $15,464.28. The filer certifies no undisclosed material adverse information.

Olema Pharmaceuticals, Inc. filed a Form 144 reporting a proposed sale of 11,914 common shares through Fidelity Brokerage Services LLC with an aggregate market value of $95,826.88. The filing lists approximately 68,634,329 shares outstanding and an approximate sale date of 09/16/2025 on the NASDAQ. The shares being offered consist of 10,000 founder shares acquired on 03/20/2007 (recorded as compensation) and 1,914 shares purchased in the open market on 06/30/2014 for cash. The filer certifies no undisclosed material adverse information about the issuer and references Rule 10b5-1 plan language if applicable.

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company advancing palazestrant (OP-1250) and a KAT6 inhibitor (OP-3136). At June 30, 2025 the company reported total cash, cash equivalents and marketable securities of $361.9 million (cash and cash equivalents of $52.5 million and marketable securities of $309.4 million) and an available balance of $22.0 million under its loan agreement; management states this liquidity is sufficient to fund the current operating plan for at least the next 12 months. Total assets were $382.0 million with stockholders' equity of $345.2 million.

For the quarter ended June 30, 2025, Olema recorded a net loss of $43.8 million (loss per share $0.51); for the six months the net loss was $74.2 million (loss per share $0.87). Research and development expense was $43.9 million for the quarter and $74.5 million for six months, which included a $10.0 million one-time milestone to Aurigene. The company drew $3.0 million under its Credit Facility and continues collaborations with Novartis and Pfizer to supply CDK4/6 inhibitors for clinical trials; it completed a 2024 private placement that generated approximately $237.0 million net proceeds and maintains an at-the-market program with $150.0 million capacity.

Olema Pharmaceuticals reported its financial results for the quarter ended June 30, 2025 and furnished a press release and an investor presentation as exhibits to this Current Report. The filing identifies the press release as Exhibit 99.1, the investor presentation as Exhibit 99.2, and the cover page interactive data file as Exhibit 104. The company states these materials are being furnished and are not deemed "filed" under Section 18 of the Exchange Act.

The 8-K does not include numerical financial metrics within the text; investors seeking revenue, earnings, or other performance figures must review the attached Exhibit 99.1 press release or Exhibit 99.2 presentation or consult the company website where the presentation was made available.